Wall Street Zen upgraded shares of Envista (NYSE:NVST – Free Report) from a buy rating to a strong-buy rating in a report released on Saturday.
A number of other brokerages also recently issued reports on NVST. JPMorgan Chase & Co. boosted their price objective on Envista from $26.00 to $29.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Piper Sandler restated a “neutral” rating and set a $28.00 target price (up from $26.00) on shares of Envista in a research note on Thursday, August 6th. BMO Capital Markets started coverage on shares of Envista in a report on Wednesday, July 8th. They set a “market perform” rating and a $27.00 price target on the stock. Mizuho set a $29.00 price target on shares of Envista in a research report on Thursday, August 6th. Finally, Barclays reduced their price objective on shares of Envista from $34.00 to $32.00 and set an “overweight” rating for the company in a research note on Thursday, June 11th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $29.31.
Get Our Latest Analysis on Envista
Envista Price Performance
Envista (NYSE:NVST – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.41 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.07. Envista had a return on equity of 7.88% and a net margin of 3.33%.The business had revenue of $730.50 million during the quarter, compared to analyst estimates of $716.11 million. During the same quarter in the previous year, the company posted $0.26 earnings per share. Envista’s revenue for the quarter was up 7.1% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. Sell-side analysts predict that Envista will post 1.53 earnings per share for the current year.
Insiders Place Their Bets
In other Envista news, SVP Mischa Reis sold 8,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $27.50, for a total transaction of $220,000.00. Following the completion of the sale, the senior vice president directly owned 27,321 shares of the company’s stock, valued at $751,327.50. This trade represents a 22.65% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.99% of the stock is owned by insiders.
Hedge Funds Weigh In On Envista
A number of hedge funds and other institutional investors have recently modified their holdings of NVST. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Envista during the second quarter valued at $25,000. Caitong International Asset Management Co. Ltd lifted its stake in Envista by 16,711.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after purchasing an additional 1,504 shares in the last quarter. Allworth Financial LP boosted its holdings in shares of Envista by 75.4% during the 4th quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock valued at $39,000 after purchasing an additional 776 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Envista by 46.1% during the 4th quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock valued at $44,000 after purchasing an additional 636 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Envista by 73.1% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock valued at $44,000 after purchasing an additional 949 shares during the last quarter.
About Envista
Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.
Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.
Read More
- Five stocks we like better than Envista
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.
